Clough Capital Partners’s AbbVie ABBV Stock Holding History

Clough Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,020	Closed	-$5.93M	–	121
2024 Q3	$5.93M	Sell	30,020 -4,270	-12%	-$797K	0.61%	51
2024 Q2	$5.88M	Buy	34,290 +31,440	+1,103%	+$5.21M	0.64%	48
2024 Q1	$519K	Hold	2,850	–	–	0.06%	104
2023 Q4	$442K	Sell	2,850 -650	-19%	-$94.8K	0.05%	140
2023 Q3	$522K	Hold	3,500	–	–	0.06%	129
2023 Q2	$472K	Hold	3,500	–	–	0.05%	154
2023 Q1	$558K	Hold	3,500	–	–	0.06%	142
2022 Q4	$566K	Buy	+3,500	New	+$537K	0.06%	142
2021 Q2	–	Sell	-83,590	Closed	-$9.05M	–	133
2021 Q1	$9.05M	Buy	83,590 +300	+0.4%	+$32.1K	0.4%	68
2020 Q4	$8.93M	Sell	83,290 -41,010	-33%	-$3.94M	0.63%	64
2020 Q3	$10.9M	Buy	+124,300	New	+$11.7M	0.78%	48
2015 Q2	–	Sell	-139,516	Closed	-$8.17M	–	192
2015 Q1	$8.17M	Sell	139,516 -174,784	-56%	-$10.6M	0.27%	110
2014 Q4	$20.6M	Sell	314,300 -168,500	-35%	-$10.6M	0.74%	47
2014 Q3	$27.9M	Buy	+482,800	New	+$26.8M	1.05%	32

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Clough Capital Partners's ABBV Position: Q4 2024 in Review

Clough Capital Partners sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 30,020 shares — an estimated $5.93M sold.

Clough Capital Partners first reported a position in ABBV in Q3 2014 and held it in 14 quarters. The position peaked at $27.9M in Q3 2014. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

Clough Capital Partners reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
Clough Capital Partners sold 30,020 AbbVie shares in Q4 2024, an estimated $5.93M.
Clough Capital Partners first reported a position in AbbVie in Q3 2014 and held it in 14 quarters.
Clough Capital Partners's AbbVie position peaked at $27.9M in Q3 2014.
3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Clough Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.